Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
September 08, 2021 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021 07:45 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
August 10, 2021 08:00 ET
|
Phathom Pharmaceuticals
Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expected in October 2021Phase 2 PHALCON-NERD on-demand trial for vonoprazan in non-erosive reflux disease enrolling...
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
August 02, 2021 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
May 11, 2021 08:00 ET
|
Phathom Pharmaceuticals
Positive Phase 3 trial of vonoprazan in Helicobacter pylori (H. pylori) infection; New Drug Applications (NDAs) targeted for the fourth quarter of 2021U.S. Food and Drug Administration (FDA) grants...
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
May 06, 2021 17:48 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
April 29, 2021 16:01 ET
|
Phathom Pharmaceuticals
Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapyNew Drug Application (NDA) submissions targeted...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
March 30, 2021 16:05 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
January 19, 2021 08:30 ET
|
Phathom Pharmaceuticals
Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,...